<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795365</url>
  </required_header>
  <id_info>
    <org_study_id>CHUV Active surveillance</org_study_id>
    <nct_id>NCT01795365</nct_id>
  </id_info>
  <brief_title>Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Active Surveillance manages selected men with prostate cancer expectantly with curative&#xD;
      intent. This means men are carefully selected and subsequently actively observed in order to&#xD;
      have the possibility to offer them curative treatment once the tumor seems to progress.&#xD;
&#xD;
      The goal of this study is to validate the treatment option Active Surveillance in men with&#xD;
      localized, well differentiated prostate cancer, in order to limit the amount of&#xD;
      overtreatment. A number of key points will be studied, such as the pathological findings in&#xD;
      radical prostatectomy specimens, and the effect of expectancy on the quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary&#xD;
&#xD;
      - To evaluate the equivalence of the time on active surveillance before an active treatment&#xD;
      between group Epstein + and the expanded active surveillance group (Epstein -)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the role of diffusion-weighted MRI (DW-MRI) in the initial diagnosis and the&#xD;
           follow-up of patients under active surveillance&#xD;
&#xD;
        -  To evaluate the role of BCAR-1 to predict the clinical outcome of localized prostate&#xD;
           cancer&#xD;
&#xD;
        -  To evaluate the proportion of patients who discontinued active surveillance&#xD;
&#xD;
        -  To evaluate the mortality at 10, 15 and 20 years from the inclusion in the study&#xD;
&#xD;
        -  To evaluate the time to radical treatment&#xD;
&#xD;
        -  To evaluate the time to metastatic disease&#xD;
&#xD;
        -  To evaluate patients quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Participants are no longer being examined and receiving intervention.&#xD;
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on active surveillance in group Epstein + and Epstein -</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor volume increased, extra-capsular extension or presence of adenopathy assessed on DW-MRI</measure>
    <time_frame>baseline, 12, 24, 48 months and every two years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCAR-1 test on biopsies</measure>
    <time_frame>baseline, 12, 24 months and every 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who discontinued active surveillance by categories (patient's will, clinical or histological criterion)</measure>
    <time_frame>Every 6 months for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of deceased patients 10, 15 and 20 years from the inclusion in the study in both groups</measure>
    <time_frame>10, 15, 20 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who progressed to a metastatic stage at different time points in both groups</measure>
    <time_frame>Every year for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Every 6 months for 6 years</time_frame>
    <description>IPSS score/IIEF-5 score( QLQ-C30 + PR25)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>Epstein + (group I)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epstein + (Group I) PSA &lt;10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;&#xD;
% of tumor biopsy invasion &lt;50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epstein - (group II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epstein - (Group II) PSA &lt;15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12&#xD;
% of tumor biopsy invasion &lt;50% and ≤8mm; mp MRI positive; T1-T2c N0 M0</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active surveillance</intervention_name>
    <arm_group_label>Epstein + (group I)</arm_group_label>
    <arm_group_label>Epstein - (group II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Localized adenocarcinoma of the prostate with a Gleason score of 3+3 (group I&#xD;
             patients) or 3+4 (group II patients)&#xD;
&#xD;
          -  Percentage of tumor biopsy invasion &lt;50% and/or with a size of maximum 8 mm&#xD;
&#xD;
          -  With a number of positive tumor biopsies ≤3 (group I patients) or ≤ 5 (group II&#xD;
             patients)&#xD;
&#xD;
          -  TNM stage T1-2a N0 M0 (group I patients); TNM stage T1-2c N0 M0 (group II patients)&#xD;
&#xD;
          -  PSA level at diagnosis &lt; 10 ng/ml for group I patients; &lt; 15 ng/ml for group II&#xD;
             patients&#xD;
&#xD;
          -  Tumor volume negative (group I patients); positive (group II patients)&#xD;
&#xD;
          -  Absence of extra-capsular extension&#xD;
&#xD;
          -  Life expectancy &gt; 10 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patient has elected active surveillance as preferred management plan for the prostate&#xD;
             cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment for prostate cancer (including hormonal therapy, radiation therapy,&#xD;
             surgery or chemotherapy)&#xD;
&#xD;
          -  Patients with hypogonadism&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Jichlinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Prof. Patrice Jichlinski</investigator_full_name>
    <investigator_title>Chief of Urology Department, University of Lausanne Hospitals</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

